Two-year safety and effectiveness of XXXX -eluting stents (from a prospective registry).

@entity1 @entity583 @entity6 @entity75 @entity3446 @entity177 @entity453 @entity204 @entity715
Uncertainty exists about the long-term safety and efficacy outcomes of @entity3446 -eluting stents (SESs) in unselected @entity1 . The present study was performed to evaluate the safety and efficacy of the SES in treatment of @entity1 with @entity453 in an unselected population. Over a 2-year period, 1,504 consecutive @entity1 undergoing percutaneous coronary intervention with >= 1 SES were enrolled. The primary end point was the occurrence of @entity177 (TVF; a composite of @entity204 , @entity583 , or clinically driven target vessel revascularization). An independent clinical event committee adjudicated all adverse events up to 2-year follow-up. Dual antiplatelet therapy was recommended for >= 1 year throughout the study period. Mean age was 65    11 years; 75% were @entity1 , and 34% were @entity6 . SESs were implanted for off-label indications in 86% of cases. TVF rates were 3.3%, 6.9%, 11.5%, and 15.5% at 30-day, 6-month, 1-year, and 2-year follow-ups, respectively. The 2-year cumulative rate of definite/probable stent @entity715 was 0.9%; 0.2% was very late @entity715 , occurring from 1 year to 2 years. @entity1 off dual antiplatelet therapy at 6 months had a significantly increased rate of subsequent death from noncardiac causes. @entity1 off dual antiplatelet therapy at 1 year had a significantly decreased rate of subsequent clinically driven @entity75 revascularization. In conclusion, use of SESs in unselected @entity1 with @entity453 was associated with a low TVF rate at 2 years with an acceptable incidence of stent @entity715 .
